InnovAge Appoints Jennifer Browne as President and COO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
InnovAge announced that Jennifer Browne has been appointed president and COO, effective June 8. Most recently, she served as the COO for Strive Health overseeing market operations and shared services.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INNV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INNV
About INNV
InnovAge Holding Corp. is a healthcare delivery platform. The Company is engaged in managing the care of high-cost, frail, and dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). Its programs are designed to allow frail seniors to live life on their terms by aging in place, in their own homes and communities, for as long as safely possible. Through its PACE program, it offers a range of medical and ancillary services for seniors, including in-home care services (skilled, unskilled and personal care), center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center, and third-party medical appointments and care management. Its participant-centered approach is led by the Company's Interdisciplinary Care Teams (IDTs), who oversee all aspects of each participant’s care plan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InnovAge Appoints New President and COO
- Executive Appointment: InnovAge announced that Jennifer Browne will serve as president and chief operating officer starting June 8, 2026, overseeing market operations and core support functions to enhance performance across operational and compliance metrics.
- Strategic Focus: Browne will concentrate on improving participant experience and execution consistency, a strategy that aims to maintain the company's competitive edge and enhance customer satisfaction in a challenging market.
- Financial Outlook: InnovAge projects revenue between $950 million and $975 million for fiscal 2026, with adjusted EBITDA expected to be between $85 million and $90 million, demonstrating resilience amid early signals of rate pressure in 2027.
- Performance Analysis: Despite InnovAge's GAAP EPS of -$0.22 missing expectations by $0.28, its revenue of $251.9 million exceeded forecasts by $17.6 million, indicating the company's potential for revenue growth.
See More
InnovAge Appoints New President and COO to Drive Growth
- Executive Appointment: InnovAge has announced the appointment of Jennifer Browne as the new President and Chief Operating Officer, effective June 8, 2026, bringing extensive experience in managing multi-state healthcare organizations under value-based care models, which is expected to enhance operational efficiency and service quality.
- Leadership Experience: Browne previously served as COO of Strive Health overseeing market operations and shared services, and before that, she was SVP of Value & Population Health at Optum, managing a value-based care portfolio of over 1.2 million patients, demonstrating her capability to scale services effectively.
- Strategic Focus: Browne's appointment reflects InnovAge's ongoing commitment to disciplined execution, regulatory excellence, and sustainable growth, aiming to improve the company's performance across key operational and compliance metrics to better serve the senior population.
- Market Expansion: As of March 31, 2026, InnovAge serves approximately 8,050 participants across 20 centers in six states, and Browne's addition is expected to further enhance the company's market reach and participant experience, driving the value of the PACE model.
See More
InnovAge Reports Q3 Fiscal 2026 Earnings Highlights
- Financial Performance Boost: InnovAge reported approximately $252 million in total revenue for Q3 FY2026, a 15.5% increase from $218.1 million in Q3 FY2025, yet faced a net loss of $29.9 million, indicating profitability challenges despite revenue growth.
- Adjusted EBITDA Guidance Raised: The company raised its FY2026 adjusted EBITDA guidance to a range of $85 million to $90 million, reflecting management's confidence in future operational trends, even amidst anticipated pressures on Medicaid rates.
- Stable Participant Numbers: As of the end of the quarter, InnovAge served approximately 8,050 participants across 20 centers in 6 states, with expectations for participant numbers to range between 7,900 and 8,100 by the end of FY2026, demonstrating market stability.
- Surge in Administrative Expenses: Corporate general and administrative expenses reached $76.5 million in Q3, a staggering 98.3% increase year-over-year, primarily driven by rising litigation liabilities, which may impact future profitability.
See More
InnovAge Q1 Earnings Report Analysis
- Disappointing Earnings: InnovAge reported a Q1 GAAP EPS of -$0.22, missing estimates by $0.28, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenue of $251.9 million, a 6.7% year-over-year increase, beating market expectations by $17.6 million, suggesting some growth potential in a competitive market.
- Increased Pre-Tax Loss: The pre-tax loss was $29.8 million, a significant increase of approximately 169.2% from $11.1 million in the same quarter last year, with the loss before income tax as a percentage of revenue rising to 11.8%, highlighting challenges in cost control.
- Improved Contribution Margin: The center-level contribution margin reached $61.0 million, up 49.8% year-over-year, representing 24.2% of revenue, an increase of 5.5 percentage points, indicating signs of improvement in core operations that may lay the groundwork for future profitability.
See More
Cirrus Logic Reports Strong Q3 Earnings, Shares Surge
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
See More
InnovAge Reports Strong Q2 2026 Earnings with Raised Guidance
- Strong Financial Performance: InnovAge reported total revenues of $239.7 million for Q2, reflecting a 14.7% year-over-year increase, with a center-level contribution margin of $52.8 million and adjusted EBITDA of $22.2 million, achieving a 9.2% EBITDA margin for the first time, indicating sustained operational and financial execution improvements.
- Improved Medicaid Environment: The company made progress in Medicaid eligibility and redeterminations, enhancing timeliness and accuracy, reducing reserves, and reinstating coverage for several participants, which is expected to further enhance participant experience and revenue.
- Raised Full-Year Guidance: InnovAge raised its fiscal 2026 full-year guidance, now expecting member months between 92,900 and 95,700, total revenue between $925 million and $950 million, and adjusted EBITDA between $70 million and $75 million, reflecting ongoing operational improvements and better-than-expected Medicaid rates.
- Governance Changes: Tom Scully returned as Chairman of the Board, with two board members rejoining, and management expressed gratitude for former leader Jim Carlson's contributions, demonstrating stability in governance and confidence in future growth.
See More
InnovAge Appoints New President and COO
- Executive Appointment: InnovAge announced that Jennifer Browne will serve as president and chief operating officer starting June 8, 2026, overseeing market operations and core support functions to enhance performance across operational and compliance metrics.
- Strategic Focus: Browne will concentrate on improving participant experience and execution consistency, a strategy that aims to maintain the company's competitive edge and enhance customer satisfaction in a challenging market.
- Financial Outlook: InnovAge projects revenue between $950 million and $975 million for fiscal 2026, with adjusted EBITDA expected to be between $85 million and $90 million, demonstrating resilience amid early signals of rate pressure in 2027.
- Performance Analysis: Despite InnovAge's GAAP EPS of -$0.22 missing expectations by $0.28, its revenue of $251.9 million exceeded forecasts by $17.6 million, indicating the company's potential for revenue growth.
See More
InnovAge Appoints New President and COO to Drive Growth
- Executive Appointment: InnovAge has announced the appointment of Jennifer Browne as the new President and Chief Operating Officer, effective June 8, 2026, bringing extensive experience in managing multi-state healthcare organizations under value-based care models, which is expected to enhance operational efficiency and service quality.
- Leadership Experience: Browne previously served as COO of Strive Health overseeing market operations and shared services, and before that, she was SVP of Value & Population Health at Optum, managing a value-based care portfolio of over 1.2 million patients, demonstrating her capability to scale services effectively.
- Strategic Focus: Browne's appointment reflects InnovAge's ongoing commitment to disciplined execution, regulatory excellence, and sustainable growth, aiming to improve the company's performance across key operational and compliance metrics to better serve the senior population.
- Market Expansion: As of March 31, 2026, InnovAge serves approximately 8,050 participants across 20 centers in six states, and Browne's addition is expected to further enhance the company's market reach and participant experience, driving the value of the PACE model.
See More
InnovAge Reports Q3 Fiscal 2026 Earnings Highlights
- Financial Performance Boost: InnovAge reported approximately $252 million in total revenue for Q3 FY2026, a 15.5% increase from $218.1 million in Q3 FY2025, yet faced a net loss of $29.9 million, indicating profitability challenges despite revenue growth.
- Adjusted EBITDA Guidance Raised: The company raised its FY2026 adjusted EBITDA guidance to a range of $85 million to $90 million, reflecting management's confidence in future operational trends, even amidst anticipated pressures on Medicaid rates.
- Stable Participant Numbers: As of the end of the quarter, InnovAge served approximately 8,050 participants across 20 centers in 6 states, with expectations for participant numbers to range between 7,900 and 8,100 by the end of FY2026, demonstrating market stability.
- Surge in Administrative Expenses: Corporate general and administrative expenses reached $76.5 million in Q3, a staggering 98.3% increase year-over-year, primarily driven by rising litigation liabilities, which may impact future profitability.
See More
InnovAge Q1 Earnings Report Analysis
- Disappointing Earnings: InnovAge reported a Q1 GAAP EPS of -$0.22, missing estimates by $0.28, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenue of $251.9 million, a 6.7% year-over-year increase, beating market expectations by $17.6 million, suggesting some growth potential in a competitive market.
- Increased Pre-Tax Loss: The pre-tax loss was $29.8 million, a significant increase of approximately 169.2% from $11.1 million in the same quarter last year, with the loss before income tax as a percentage of revenue rising to 11.8%, highlighting challenges in cost control.
- Improved Contribution Margin: The center-level contribution margin reached $61.0 million, up 49.8% year-over-year, representing 24.2% of revenue, an increase of 5.5 percentage points, indicating signs of improvement in core operations that may lay the groundwork for future profitability.
See More
Cirrus Logic Reports Strong Q3 Earnings, Shares Surge
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
See More
InnovAge Reports Strong Q2 2026 Earnings with Raised Guidance
- Strong Financial Performance: InnovAge reported total revenues of $239.7 million for Q2, reflecting a 14.7% year-over-year increase, with a center-level contribution margin of $52.8 million and adjusted EBITDA of $22.2 million, achieving a 9.2% EBITDA margin for the first time, indicating sustained operational and financial execution improvements.
- Improved Medicaid Environment: The company made progress in Medicaid eligibility and redeterminations, enhancing timeliness and accuracy, reducing reserves, and reinstating coverage for several participants, which is expected to further enhance participant experience and revenue.
- Raised Full-Year Guidance: InnovAge raised its fiscal 2026 full-year guidance, now expecting member months between 92,900 and 95,700, total revenue between $925 million and $950 million, and adjusted EBITDA between $70 million and $75 million, reflecting ongoing operational improvements and better-than-expected Medicaid rates.
- Governance Changes: Tom Scully returned as Chairman of the Board, with two board members rejoining, and management expressed gratitude for former leader Jim Carlson's contributions, demonstrating stability in governance and confidence in future growth.
See More
